7-bromo-5-pyrido-1,4-benzodiazepin-2-one | 1812-33-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: 7-bromo-5-pyrido-1,4-benzodiazepin-2-one
• 英文别名: 7-Brom-2-oxo-1-methyl-5--2.3-dihydro-1H-benzo<1.4>diazepin；Methylbromazepam；7-bromo-1-methyl-5-pyridin-2-yl-1,3-dihydro-benzo[e][1,4]diazepin-2-one；N-Methylbromazepam；7-bromo-1-methyl-5-pyridin-2-yl-3H-1,4-benzodiazepin-2-one
• CAS: 1812-33-5
• 化学式: C₁₅H₁₂BrN₃O
• 分子量: 330.184
• InChiKey: GIBKFDFZIZIKGJ-UHFFFAOYSA-N

物化性质

• 熔点：
  135.5-137.0 °C
• 沸点：
  534.6±50.0 °C(Predicted)
• 密度：
  1.51±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  45.6
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  7-bromo-5-pyrido-1,4-benzodiazepin-2-one 、 丙酮 在 正丁基锂 、 二异丙胺 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 0.5h， 以18%的产率得到7-bromo-3-(1'-hydroxy-1-methylethyl)-5-(2'-pyridyl)-2,3-dihydro-1H-1,4-benzodiazepin-2-one
  参考文献：
  名称：

  Kinetic resolution of diastereomeric racemates of 7-bromo-3-(1′-hydroxyethyl)-1-methyl-5-(2′-pyridyl)-2,3-dihydro-1H-1,4-benzodiazepin-2-one by immobilized CAL-B

  摘要：

  Immobilized CAL-B catalyzed kinetic resolution of syn-7-bromo-3-(1'-hydroxyethyl)-1-methyl-5-(2'-pyridyl)-2,3-dihydro-1H-1,4-benzodiazepin-2-one syn-(+/-)-2 and its anti-diastereomer (+/-)-3 were achieved with E-values over 200. Completely enantioselective acetylation of (1'R)-enantiomers in diastereomeric racemates with an opposite configuration at the second stereogenic center C(3) occured at substantially different rate (t(1/2syn)/t(1/2anti) ca. 1/20). Conformational origins of enantioselection are also discussed. (C) 2003 Published by Elsevier Ltd.

  DOI：

  10.1016/s0957-4166(03)00569-x

文献信息

• Majeric-Elenkov, Maja; Ziher, Dinko; Visnjevac, Aleksandar, Croatica Chemica Acta, 2001, vol. 74, # 3, p. 707 - 724
  作者：Majeric-Elenkov, Maja、Ziher, Dinko、Visnjevac, Aleksandar、Hamersak, Zdenko、Kojic-Prodic, Biserka、Sunjic, Vitomir

  DOI：——

  日期：——
• MULTI-API LOADING PRODRUGS
  申请人：Alkermes Pharma Ireland Limited

  公开号：US20180194732A1

  公开（公告）日：2018-07-12

  The present invention accomplishes this by having multiple molecules of parent drugs attached to carrier moieties and by extending the period during which the parent drug is released and absorbed after administration to the patient and providing a longer duration of action per dose than the parent drug itself. Prodrug conjugates are suitable for sustained delivery of heteroaryl, lactam- amide-, imide-, sulfonamide-, carbamate-, urea-, benzamide-, acylaniline-, cyclic amide- and tertiary amine-containing parent drugs that are substituted at the amide nitrogen or oxygen atom with labile aldehyde-linked prodrug moieties. The carrier groups of the prodrugs can be hydrophobic to reduce the polarity and solubility of the parent drug under physiological conditions.
• Kinetic resolution of diastereomeric racemates of 7-bromo-3-(1′-hydroxyethyl)-1-methyl-5-(2′-pyridyl)-2,3-dihydro-1H-1,4-benzodiazepin-2-one by immobilized CAL-B
  作者：Maja Majerić Elenkov、Zdenko Hameršak、Vitomir Šunjić

  DOI：10.1016/s0957-4166(03)00569-x

  日期：2003.9

  Immobilized CAL-B catalyzed kinetic resolution of syn-7-bromo-3-(1'-hydroxyethyl)-1-methyl-5-(2'-pyridyl)-2,3-dihydro-1H-1,4-benzodiazepin-2-one syn-(+/-)-2 and its anti-diastereomer (+/-)-3 were achieved with E-values over 200. Completely enantioselective acetylation of (1'R)-enantiomers in diastereomeric racemates with an opposite configuration at the second stereogenic center C(3) occured at substantially different rate (t(1/2syn)/t(1/2anti) ca. 1/20). Conformational origins of enantioselection are also discussed. (C) 2003 Published by Elsevier Ltd.